A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.

@article{Bauer2006APE,
  title={A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.},
  author={Martin Bauer and Oliver Langer and Peter Dal-Bianco and Rudolf Karch and M. Brunner and Aiman Abrahim and Rupert Lanzenberger and Andrea Hofmann and Christian Joukhadar and Paolo Carminati and Orlando Ghirardi and Paola Piovesan and Gianluigi Forloni and Mario Ermanno Corrado and Nad{\`e}ge Lods and Robert Dudczak and E. Auff and Kurt Kletter and Markus U. M{\"u}ller},
  journal={Clinical pharmacology and therapeutics},
  year={2006},
  volume={80 3},
  pages={
          216-27
        }
}
This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1'-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

PET microdosing of CNS drugs

  • Clinical and Translational Imaging
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

The Use of Microdosing in the Development of Small Organic and Protein Therapeutics.

  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2017